The Spectra Optia continuous mononuclear cell (CMNC) program is newly available, and herein validated in a single-center cohort enriched with AL amyloidosis patients to collect a target CD34+ yield of 2.5 × 106 cells/kg within 2 days.



Spectra Optia
Patients undergo leukapheresis with Optia CMNC and Spectra v4.7 over a 2-day cycle.  The Optia CMNC collection protocol is safe and effective in a small single-center autologous stem cell transplant cohort enriched for high-risk patients with AL amyloidosis and cardiac involvement. 
Optia CMNC
Patients undergo leukapheresis with Optia CMNC and Spectra v4.7 over a 2-day cycle. 
Spectra v4.7